GoAI
Get started
Cognition Therapeutics, Inc. logo

Cognition Therapeutics, Inc.

CGTX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.9959

+$0.0392 · +4.10%

Aug 21, 4:00 PM ET

CGTX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

25

Expensive

Momentum

30

Weakening

Sentiment

71

Bullish

Risk resilience

25

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Lisa Ricciardi
Listed since
Oct 8, 2021
Employees
14

Market position

Day range

Current $0.9959

52-week range

Current $0.9959

Open
$0.975
Previous close
$0.9567
Volume
308.33K
0.25× average
Average volume
1.25M
Average daily volume
Market cap
89.13M USD
Beta
1.78
Market reference 1
50-day average
$1.0757
-7.41% below average
200-day average
$1.2226
-18.54% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
62.06M USD
EV / EBITDA
-2.67×
Earnings yield
-23.91%
Free cash flow yield
-25.03%

Profitability & efficiency

Return on equity
-68.53%
Return on assets
-48.54%
Return on invested capital
-136.92%

Financial health

Current ratio
3.45×
Altman Z-score
1.24
Piotroski F-score
1 of 9

Financial statements

Income trends

Operating income

−47.8M USD+11.43%

Net income

−23.49M USD+30.86%
Income trends across reported periods6.23M USD−15.66M USD−37.55M USD−59.44M USDOperating income, FY2021: −28.6M USDOperating income, FY2022: −43.55M USDOperating income, FY2023: −50.72M USDOperating income, FY2024: −53.97M USDOperating income, FY2025: −47.8M USDNet income, FY2021: −11.72M USDNet income, FY2022: 757K USDNet income, FY2023: −25.79M USDNet income, FY2024: −33.97M USDNet income, FY2025: −23.49M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −28.6M USD. Operating income FY2022 −43.55M USD. Operating income FY2023 −50.72M USD. Operating income FY2024 −53.97M USD. Operating income FY2025 −47.8M USD. Net income FY2021 −11.72M USD. Net income FY2022 757K USD. Net income FY2023 −25.79M USD. Net income FY2024 −33.97M USD. Net income FY2025 −23.49M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold———235K USD—
Gross profit———−235K USD—
Research and development37.19M USD41.68M USD37.2M USD30.32M USD18.57M USD
Selling, general, and administrative10.61M USD12.29M USD13.53M USD13.23M USD10.03M USD
Operating expenses47.8M USD53.97M USD50.72M USD43.32M USD28.6M USD
Interest income——24.81M USD22.22M USD17.45M USD
Interest expense13K USD25K USD27K USD28K USD893K USD
Depreciation and amortization228K USD266K USD252K USD235K USD93K USD
Operating income−47.8M USD−53.97M USD−50.72M USD−43.55M USD−28.6M USD
Net income−23.49M USD−33.97M USD−25.79M USD757K USD−11.72M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+13.22%
11 comparable reports
Latest EPS result
-0.04
Estimate -0.06 · Beat by 36.84%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.02-0.08-0.15-0.21Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual -0.17, estimate -0.16, surprise -6.25%, Miss. Q2 2025, reported May 7, 2025: actual -0.14, estimate -0.12, surprise -16.67%, Miss. Q3 2025, reported Aug 7, 2025: actual -0.11, estimate -0.12, surprise +8.33%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.06, estimate -0.07, surprise +14.29%, Beat. Q1 2026, reported Mar 26, 2026: actual -0.02, estimate -0.06, surprise +66.67%, Beat. Q2 2026, reported May 7, 2026: actual -0.05, estimate -0.06, surprise +16.67%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.04, estimate -0.063, surprise +36.84%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.07, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.69M3.9M2.11M316.2KQ1 '24No estimateQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q1 2024, reported Mar 26, 2024: actual 372K USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 7, 2026: actual —, estimate 4.4M USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 6, 2026: actual —, estimate 5M USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 5, 2026: actual —, estimate 5.3M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

7 ratings
Strong buy00%
Buy686%
Hold114%
Sell00%
Strong sell00%

CGTX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CGTX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.17M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
821.9K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
266.78K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
iShares Neuroscience and Healthcare ETF logoiShares Neuroscience and Healthcare ETFIBRN
Market value
5.79K
Weight
0.07%
AUM
7.92M USD
Expense ratio
0.47%
Price / 1D
$39.62+0.61%

Continue in GoAI

Research CGTX

research.disclaimer